Association Between Chronic Obstructive Pulmonary Disease and All-Cause Mortality After Aortic Valve Replacement for Aortic Stenosis

https://doi.org/10.1016/j.amjcard.2022.11.007Get rights and content
Under a Creative Commons license
open access

Chronic obstructive pulmonary disease (COPD) and aortic stenosis (AS) are the most common diseases in which age plays a major role in the increase of their prevalence and when they co-exist, the outcomes prognosis worsens significantly. The aim of the present study was to evaluate the association between pulmonary functional parameters and all-cause mortality after aortic valve replacement (transcatheter or surgical). A total of 400 patients with severe AS and preoperative pulmonary functional test were retrospectively analyzed. Echocardiography and pulmonary functional parameters before aortic valve replacement were collected. COPD severity was defined according to criteria from the Society of Thoracic Surgeons. COPD was present in 128 patients (32%) with severe AS. Patients without COPD had smaller left ventricular (LV) mass and LV end-systolic volume and better LV function than the group with COPD. During a median follow-up of 32 months, 92 patients (23%) died. The survival rates were significantly lower in patients with moderate and severe COPD (log-rank p = 0.003). In the multivariable Cox regression analysis, any grade of COPD was associated with an approximately 2-fold increased risk of all-cause mortality (hazard ratio 1.933; 95% confidence interval 1.166 to 3.204; p = 0.011 for mild COPD and hazard ratio 2.028; 95% confidence interval 1.154 to 3.564; p = 0.014 for moderate or severe COPD). In addition to other clinical factors, any grade of COPD was associated with 2-fold increased risk of all-cause mortality.

Cited by (0)

Funding: Rinchyenkhand Myagmardorj received funding from the European Association of Cardiovascular Imaging (EACVI Training Grant App000073275). K.H. received an ESC Research Grant (R-2018-18122). The Department of Cardiology, Heart Lung Center, Leiden University Medical Centre has received research grants from Abbott Vascular, Bayer, Biotronik, Bioventrix, Boston Scientific, Edwards Lifesciences, GE Healthcare, Ionis, Medtronic and Novartis. N.A.M. received speaker fees from Abbott Vascular and GE Healthcare. J.J.B. received speaker fees from Abbott Vascular and Edwards Lifesciences. V.D received speaker fees from Abbott Vascular, Medtronic, Edwards Lifesciences, Novartis and GE Healthcare..